5444492026-02-232026-02-235444492026-02-235444492026-02-232026-02-23

PartiesOfTheAgreementDomain1

5444492026-02-23

PartiesOfTheAgreementDomain1

5444492026-02-232026-02-23

PartiesOfTheAgreementDomain2

5444492026-02-23

PartiesOfTheAgreementDomain2

xbrli:purexbrli:shares

Anthem Biosciences Limited

ANTHEM

New

Others

First Amendment to the Loan Agreement dated April 15, 2024

Execution of agreement

Listed Entity,Others

Wholly Owned Subsidiary

false

2026-02-23

15:30:00

true

2026-02-23

The First Amendment Agreement has been entered into to convert an additional amount of up to Rs 275,00,00,000 (Rupees Two Hundred and Seventy Five Crores Only) of the loan into equity shares of Neoanthem, within the overall sanctioned financial assistance limit of Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores).

2025-11-08

true

Not Applicable as the Borrowing Company is Wholly Owned Subsidiary Company

Anthem Biosciences Limited

Party entering into the agreement

Yes

100149999

true

Neoanthem Lifesciences Private Limited is a wholly owned subsidiary of the Company and forms part of the Company’s group structure

Neoanthem Lifesciences Private Limited

Counterparties to the agreement

true

Neoanthem Lifesciences Private Limited is a wholly owned subsidiary of the Company and forms part of the Company’s group structure

true

2026-02-23

(i) The Company has sanctioned financial assistance of up to Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores) to Neoanthem Lifesciences Private Limited pursuant to the Board Resolution dated June 27, 2024. (ii) The original terms as per the Original Loan Agreement included an option to convert up to Rs. 100,00,00,000 (Rupees Hundred Crore Only) of the financial assistance into equity shares of Neoanthem, which was exercised on February 21, 2025. (iii) Pursuant to the First Amendment Agreement, the Company has been granted an option to convert an additional amount of up to Rs. 275,00,00,000 (Rupees Two Hundred and Seventy-Five Crores Only), out of the sanctioned financial assistance limit, into fully paid-up equity shares of Neoanthem, at its discretion and subject to applicable approvals at the time of conversion. (iv) The financial assistance is in the nature of an unsecured loan. (v) The loan carries interest as per the terms mutually agreed between the parties under the Loan Agreement.

false

Nil

Pursuant to the approval of the Board of Directors on March 14, 2024, the Company had entered into a Loan Agreement dated April 15, 2024 (the “Original Loan Agreement”) for provision of financial assistance of up to Rs. 300,00,00,000 (Rupees Three Hundred Crores Only) to Neoanthem Lifesciences Private Limited, including an option to convert up to Rs. 100,00,00,000 (Rupees One Hundred Crores Only) into equity shares. The overall financial assistance limit was subsequently enhanced to Rs. 550,00,00,000 (Rupees Five Hundred and Fifty Crores) pursuant to a Board Resolution dated June 27, 2024. In accordance with the terms of the Original Loan Agreement and upon obtaining the requisite approvals from the Board and Shareholders of Neoanthem, Rs. 100,00,00,000 (Rupees One Hundred Crores Only) was converted into equity shares on February 21, 2025. Pursuant to Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in connection with the proposed listing of the Company, the requisite approvals of the Audit Committee and the Board of Directors were obtained on June 9, 2025. Further, the transaction being a material related party transaction, approval of the Shareholders was also obtained at the Annual General Meeting held on June 10, 2025. Further, at its meeting held on November 8, 2025, the Board approved the conversion of an additional amount of Rs 275,00,00,000 (Rupees Two Hundred and Seventy Five Crores Only) of the loan into equity which has been formalised pursuant to the First Amendment Agreement dated February 23, 2026.